Orion Oyj (ORINY) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ORINY steht fuer Orion Oyj, ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Die Aktie erzielt 64/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 16. März 2026Orion Oyj (ORINY) Gesundheitswesen & Pipeline-Uebersicht
Orion Oyj, a Finnish pharmaceutical company established in 1917, develops, manufactures, and markets a diverse portfolio of human and veterinary pharmaceuticals, along with active pharmaceutical ingredients (APIs). The company's global reach extends to Europe, North America, and other international markets, serving healthcare providers and consumers with prescription and self-care products.
Investmentthese
Orion Oyj presents a compelling investment case based on its diversified product portfolio, global presence, and strong financial performance. The company's focus on both human and veterinary pharmaceuticals, along with its API business, provides multiple revenue streams and reduces dependence on any single product. With a market capitalization of $21.77 billion and a profit margin of 26.5%, Orion demonstrates financial stability and profitability. The company's dividend yield of 2.32% offers an attractive income stream for investors. Key growth catalysts include the expansion of its oncology portfolio with Nubeqa and the continued success of its Easyhaler products. However, potential risks include regulatory challenges, competition from generic drug manufacturers, and currency fluctuations.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $21.77 billion reflects a substantial valuation in the pharmaceutical sector.
- Profit margin of 26.5% indicates strong operational efficiency and profitability.
- Gross margin of 64.2% demonstrates effective cost management in manufacturing and sales.
- Dividend yield of 2.32% provides a steady income stream for investors.
- Beta of 0.36 suggests lower volatility compared to the overall market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Diversified product portfolio across human and veterinary pharmaceuticals.
- Global presence with sales in Europe, North America, and other international markets.
- Strong research and development capabilities.
- Strategic partnerships with other pharmaceutical companies and research institutions.
Schwaechen
- Dependence on key products for revenue generation.
- Exposure to regulatory risks and patent expirations.
- Limited presence in emerging markets.
- Competition from larger pharmaceutical companies.
Katalysatoren
- Ongoing: Expansion of Nubeqa sales for prostate cancer treatment.
- Ongoing: Growth of Easyhaler product line for asthma and COPD.
- Upcoming: Potential regulatory approvals for new pharmaceutical products.
- Ongoing: Strategic partnerships and collaborations to drive innovation.
- Ongoing: Development of new veterinary pharmaceuticals.
Risiken
- Potential: Competition from generic drug manufacturers.
- Potential: Pricing pressures from healthcare providers and payers.
- Potential: Regulatory changes and patent challenges.
- Potential: Economic downturns and currency fluctuations.
- Ongoing: Dependence on key products for revenue generation.
Wachstumschancen
- Expansion of Oncology Portfolio: Orion's Nubeqa, used for treating prostate cancer, presents a significant growth opportunity. The global prostate cancer therapeutics market is projected to reach billions of dollars by 2028. Orion can capitalize on this market by expanding its sales and marketing efforts, conducting further clinical trials to explore new indications, and securing regulatory approvals in additional markets. This expansion will drive revenue growth and enhance Orion's position in the oncology space.
- Easyhaler Product Line: Orion's Easyhaler product portfolio for asthma and COPD offers a strong growth avenue. The global respiratory inhalers market is expected to grow, driven by the increasing prevalence of respiratory diseases and technological advancements in inhaler devices. Orion can leverage its partnership with Propeller Health to enhance the connectivity and adherence of its Easyhaler products, differentiating them from competitors and driving market share gains. The company should focus on expanding its Easyhaler offerings to new markets and developing innovative formulations.
- Veterinary Pharmaceuticals: Orion's veterinary pharmaceuticals business provides a stable and growing revenue stream. The global animal health market is driven by the increasing pet ownership and rising demand for animal protein. Orion can expand its veterinary portfolio by developing and marketing new products for companion animals and livestock. The company should also explore opportunities to expand its geographic reach and distribution network in the veterinary market.
- Active Pharmaceutical Ingredients (APIs): Orion's API business offers a growth opportunity by supplying APIs for generic and proprietary drugs. The global API market is driven by the increasing demand for affordable medicines and the growing generic drug market. Orion can strengthen its API business by expanding its manufacturing capacity, developing new APIs, and securing contracts with generic drug manufacturers. The company should also focus on developing high-quality APIs that meet stringent regulatory standards.
- Strategic Partnerships and Collaborations: Orion can drive growth through strategic partnerships and collaborations with other pharmaceutical companies and research institutions. The company's research collaboration with Alligator Bioscience AB to develop bispecific antibody cancer therapeutics demonstrates its commitment to innovation. Orion should continue to seek out partnerships that can enhance its product pipeline, expand its market reach, and accelerate its research and development efforts. These collaborations will provide access to new technologies and expertise, driving long-term growth.
Chancen
- Expansion of oncology portfolio with Nubeqa.
- Growth of Easyhaler product line for asthma and COPD.
- Development of new veterinary pharmaceuticals.
- Expansion into emerging markets.
Risiken
- Competition from generic drug manufacturers.
- Pricing pressures from healthcare providers and payers.
- Regulatory changes and patent challenges.
- Economic downturns and currency fluctuations.
Wettbewerbsvorteile
- Diversified product portfolio across human and veterinary pharmaceuticals.
- Global presence with sales in Europe, North America, and other international markets.
- Strong research and development capabilities.
- Strategic partnerships with other pharmaceutical companies and research institutions.
Ueber ORINY
Founded in 1917 and headquartered in Espoo, Finland, Orion Oyj has evolved into a prominent pharmaceutical company with a global footprint. The company develops, manufactures, and markets a broad range of human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients (APIs). Orion's human pharmaceuticals include prescription drugs for various therapeutic areas, such as oncology (Nubeqa for prostate cancer), critical care (dexdor and Precedex), neurology (Stalevo and Comtess/Comtan for Parkinson's disease), cardiology (Simdax for acute decompensated heart failure), and oncology (Fareston for breast cancer). Additionally, Orion offers a range of Easyhaler products for asthma and chronic obstructive pulmonary disease (COPD). The company's veterinary drugs portfolio includes products like Bonqat, Clevor, Domosedan, Domitor, and Sileo. Orion also provides APIs for generic and proprietary drugs and offers contract manufacturing services. The company serves healthcare service providers, professionals, and consumers with pets across Finland, Scandinavia, other European countries, North America, and internationally. Orion has strategic partnerships, including one with Propeller Health to enhance its Easyhaler product portfolio and a research collaboration with Alligator Bioscience AB to develop bispecific antibody cancer therapeutics.
Was das Unternehmen tut
- Develops and manufactures human pharmaceuticals.
- Markets prescription drugs for various therapeutic areas, including oncology, neurology, and cardiology.
- Offers self-care products for consumers.
- Develops and manufactures veterinary pharmaceuticals for companion animals and livestock.
- Provides active pharmaceutical ingredients (APIs) for generic and proprietary drugs.
- Offers contract manufacturing services to other pharmaceutical companies.
- Markets and sells veterinary drugs manufactured by other international companies.
Geschaeftsmodell
- Develops and manufactures pharmaceutical products.
- Sells products through a network of healthcare service providers, professionals, and pharmacies.
- Generates revenue from prescription drugs, self-care products, veterinary drugs, and APIs.
- Partners with other companies for research, development, and distribution.
Branchenkontext
Orion Oyj operates in the global pharmaceutical industry, which is characterized by intense competition, stringent regulatory requirements, and continuous innovation. The market is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. Orion competes with major pharmaceutical companies, including ALPMF (Alphamab Oncology), ALPMY (Almirall SA), CLPBY (Clinigen Group), GIKLY (Grifols SA), and OTSKF (Otsuka Holdings). The company's focus on niche markets, such as veterinary pharmaceuticals and Easyhaler products, helps it differentiate itself from larger competitors. The global pharmaceuticals market is expected to continue growing, driven by increased healthcare spending and demand for innovative therapies.
Wichtige Kunden
- Specialist and general practitioners.
- Veterinarians.
- Pharmacies.
- Hospitals and healthcare centers.
- Clinics and laboratories.
- Consumers with pets.
Finanzdaten
Chart & Info
Orion Oyj (ORINY) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer ORINY verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer ORINY.
Kursziele
Wall-Street-Kurszielanalyse fuer ORINY.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von ORINY auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Liisa Hurme
CEO
Liisa Hurme serves as the CEO of Orion Oyj. Her career spans various leadership roles within the pharmaceutical industry. She brings extensive experience in strategic management, business development, and commercial operations. Hurme's background includes a strong focus on driving innovation and growth in the healthcare sector. Her leadership is characterized by a commitment to scientific excellence and patient-centric solutions. She oversees a workforce of 3943 employees.
Erfolgsbilanz: Under Liisa Hurme's leadership, Orion Oyj has focused on expanding its oncology portfolio and strengthening its position in respiratory therapies. Key achievements include the successful launch of Nubeqa for prostate cancer and the continued growth of the Easyhaler product line. Hurme has also emphasized strategic partnerships and collaborations to drive innovation and expand the company's market reach. Her tenure has been marked by a focus on sustainable growth and shareholder value.
Orion Oyj ADR-Informationen Nicht gesponsert
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. ORINY functions as a Level 1 ADR, meaning it trades over-the-counter (OTC) without the stringent requirements of listed exchanges. This allows U.S. investors to invest in Orion Oyj without directly dealing with foreign markets.
- Heimatmarkt-Ticker: Nasdaq Helsinki, Finland
- ADR-Stufe: 1
- ADR-Verhaeltnis: 1:1
- Heimatmarkt-Ticker: ORIN
ORINY OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Orion Oyj (ORINY) has chosen not to meet the minimum financial and disclosure standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation compared to NYSE/NASDAQ-listed companies.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited regulatory oversight and disclosure requirements.
- Potential for fraud or manipulation.
- Illiquidity and wide bid-ask spreads.
- Higher price volatility.
- Difficulty in obtaining reliable information about the company.
- Verify the company's registration and legal status.
- Obtain and review the company's financial statements, if available.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Determine if the company has plans to uplist to a major exchange.
- Established history as a Finnish pharmaceutical company since 1917.
- Presence in the human and veterinary pharmaceutical markets.
- Partnerships with other pharmaceutical companies and research institutions.
- Availability of information on the company's website and in press releases.
- Listing on the Nasdaq Helsinki stock exchange (ORIN).
Orion Oyj Aktie: Wichtige Fragen beantwortet
What are the key factors to evaluate for ORINY?
Orion Oyj (ORINY) currently holds an AI score of 64/100, indicating moderate score. Key strength: Diversified product portfolio across human and veterinary pharmaceuticals.. Primary risk to monitor: Potential: Competition from generic drug manufacturers.. This is not financial advice.
How frequently does ORINY data refresh on this page?
ORINY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ORINY's recent stock price performance?
Recent price movement in Orion Oyj (ORINY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diversified product portfolio across human and veterinary pharmaceuticals.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ORINY overvalued or undervalued right now?
Determining whether Orion Oyj (ORINY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ORINY?
Before investing in Orion Oyj (ORINY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ORINY to a portfolio?
Potential reasons to consider Orion Oyj (ORINY) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Diversified product portfolio across human and veterinary pharmaceuticals.. Additionally: Global presence with sales in Europe, North America, and other international markets.. The AI-driven MoonshotScore of 64/100 reflects solid quantitative fundamentals. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of ORINY?
Yes, most major brokerages offer fractional shares of Orion Oyj (ORINY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ORINY's earnings and financial reports?
Orion Oyj (ORINY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for ORINY earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than data from major exchanges.